| Model cell membranes: Techniques to form complex biomimetic supported lipid bilayers via vesicle fusion GJ Hardy, R Nayak, S Zauscher Current opinion in colloid & interface science 18 (5), 448-458, 2013 | 262 | 2013 |
| Financial toxicity in cancer care: origins, impact, and solutions HR Abrams, S Durbin, CX Huang, SF Johnson, RK Nayak, GJ Zahner, ... Translational behavioral medicine 11 (11), 2043-2054, 2021 | 138 | 2021 |
| Public sector financial support for late stage discovery of new drugs in the United States: cohort study RK Nayak, J Avorn, AS Kesselheim bmj 367, 2019 | 78 | 2019 |
| Pragmatic randomized trials without standard informed consent? A national survey RK Nayak, D Wendler, FG Miller, SYH Kim Annals of internal medicine 163 (5), 356-364, 2015 | 61 | 2015 |
| Biomimetic supported lipid bilayers with high cholesterol content formed by α-helical peptide-induced vesicle fusion GJ Hardy, R Nayak, SM Alam, JG Shapter, F Heinrich, S Zauscher Journal of materials chemistry 22 (37), 19506-19513, 2012 | 61 | 2012 |
| The ethics of ‘fail first’: guidelines and practical scenarios for step therapy coverage policies RK Nayak, SD Pearson Health Affairs 33 (10), 1779-1785, 2014 | 36 | 2014 |
| Should social value obligations be local or global? R Nayak, SK Shah Bioethics 31 (2), 116-127, 2017 | 15 | 2017 |
| Estimation of out-of-pocket costs for guideline-directed medical therapy for heart failure under Medicare Part D and the Inflation Reduction Act M Johnson, RK Nayak, L Gilstrap, SB Dusetzina JAMA cardiology 8 (3), 299-301, 2023 | 14 | 2023 |
| Public-sector contributions to novel biologic drugs RK Nayak, CWC Lee, J Avorn, AS Kesselheim JAMA Internal Medicine 181 (11), 1522-1525, 2021 | 10 | 2021 |
| Which drug prices will Medicare negotiate first? A physicians’ perspective M Johnson, R Nayak, S Kishore Health Affairs Forefront, 2022 | 8 | 2022 |
| Maintenance therapy for AML after allogeneic HCT RK Nayak, YB Chen Frontiers in Oncology 12, 895771, 2022 | 7 | 2022 |
| HIV-1 antibodies and vaccine antigen selectively interact with lipid domains GJ Hardy, GC Wong, R Nayak, K Anasti, M Hirtz, JG Shapter, SM Alam, ... Biochimica et Biophysica Acta (BBA)-Biomembranes 1838 (10), 2662-2669, 2014 | 6 | 2014 |
| Cost-related motivations for conducting research: participants should be informed RK Nayak, SD Pearson, FG Miller JAMA 311 (15), 1491-1492, 2014 | 5 | 2014 |
| Characteristics of public vs. private federally qualified health centers S Kishore, M Johnson, R Nayak Journal of General Internal Medicine 37 (4), 987-989, 2022 | 3 | 2022 |
| 340B—Where do we go from here? S Kishore, RK Nayak, AS Kesselheim JAMA, 2023 | 1 | 2023 |
| SOHO State of the Art Updates and Next Questions| Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors RK Nayak, D Gerber, C Zhang, JB Cohen Clinical Lymphoma Myeloma and Leukemia, 2023 | 1 | 2023 |
| The Inflation Reduction Act: how will Medicare negotiating drug prices impact patients with heart disease? M Johnson, S Kishore, RK Nayak, SB Dusetzina Current Cardiology Reports 25 (6), 577-581, 2023 | 1 | 2023 |
| Cognitive Tests and Stool Frequency at Hospital Discharge Do Not Predict Outcomes in Hepatic Encephalopathy. PP Bloom, SJ Miller, RK Nayak, MS Hussain, A Arvind, C Bay, RT Chung Southern Medical Journal 113 (11), 578-584, 2020 | 1 | 2020 |
| Is it important to disclose how treatments are selected in clinical research and clinical care? RK Nayak, D Wendler AJOB Empirical Bioethics 8 (3), 170-177, 2017 | 1 | 2017 |
| The high costs of anticancer therapies in the USA: challenges, opportunities and progress SA Jazowski, RK Nayak, SB Dusetzina Nature Reviews Clinical Oncology 21 (12), 888-899, 2024 | | 2024 |
